These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21346734)

  • 1. Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy.
    Friedman JI; Lindenmayer JP; Alcantara F; Bowler S; Parak M; White L; Iskander A; Parrella M; Adler DN; Tsopelas ND; Tsai WY; Novakovic V; Harvey PD; Davis KL; Kaushik S
    Neuropsychopharmacology; 2011 May; 36(6):1289-95. PubMed ID: 21346734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia.
    Gunduz-Bruce H; Oliver S; Gueorguieva R; Forselius-Bielen K; D'Souza DC; Zimolo Z; Tek C; Kaliora S; Ray S; Petrides G
    Schizophr Res; 2013 Feb; 143(2-3):344-7. PubMed ID: 23219861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness.
    Barnes TR; Leeson VC; Paton C; Marston L; Davies L; Whittaker W; Osborn D; Kumar R; Keown P; Zafar R; Iqbal K; Singh V; Fridrich P; Fitzgerald Z; Bagalkote H; Haddad PM; Husni M; Amos T
    Health Technol Assess; 2017 Sep; 21(49):1-56. PubMed ID: 28869006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.
    Josiassen RC; Joseph A; Kohegyi E; Stokes S; Dadvand M; Paing WW; Shaughnessy RA
    Am J Psychiatry; 2005 Jan; 162(1):130-6. PubMed ID: 15625211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review.
    Kontaxakis VP; Ferentinos PP; Havaki-Kontaxaki BJ; Roukas DK
    Eur Psychiatry; 2005 Aug; 20(5-6):409-15. PubMed ID: 16171655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial.
    Freudenreich O; Henderson DC; Macklin EA; Evins AE; Fan X; Cather C; Walsh JP; Goff DC
    J Clin Psychiatry; 2009 Dec; 70(12):1674-80. PubMed ID: 19689921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
    Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
    J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial.
    Assion HJ; Reinbold H; Lemanski S; Basilowski M; Juckel G
    Pharmacopsychiatry; 2008 Jan; 41(1):24-8. PubMed ID: 18203048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine.
    Ball MP; Warren KR; Feldman S; McMahon RP; Kelly DL; Buchanan RW
    Clin Schizophr Relat Psychoses; 2011 Apr; 5(1):17-25. PubMed ID: 21459735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Lin CH; Lin CH; Chang YC; Huang YJ; Chen PW; Yang HT; Lane HY
    Biol Psychiatry; 2018 Sep; 84(6):422-432. PubMed ID: 29397899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study.
    Muscatello MR; Pandolfo G; Micò U; Lamberti Castronuovo E; Abenavoli E; Scimeca G; Spina E; Zoccali R; Bruno A
    J Clin Psychopharmacol; 2014 Feb; 34(1):129-33. PubMed ID: 24145221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
    Lerner V; Miodownik C; Gibel A; Sirota P; Bush I; Elliot H; Benatov R; Ritsner MS
    J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and protocol for the Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial: a randomised controlled trial.
    Pyle M; Norrie J; Schwannauer M; Kingdon D; Gumley A; Turkington D; Byrne R; Syrett S; MacLennan G; Dudley R; McLeod HJ; Griffiths H; Bowe S; Barnes TR; French P; Hutton P; Davies L; Morrison AP
    BMC Psychiatry; 2016 Aug; 16():280. PubMed ID: 27496180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.
    Anil Yağcioğlu AE; Kivircik Akdede BB; Turgut TI; Tümüklü M; Yazici MK; Alptekin K; Ertuğrul A; Jayathilake K; Göğüş A; Tunca Z; Meltzer HY
    J Clin Psychiatry; 2005 Jan; 66(1):63-72. PubMed ID: 15669890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risperidone augmentation of clozapine: a critical review.
    Kontaxakis VP; Ferentinos PP; Havaki-Kontaxaki BJ; Paplos KG; Pappa DA; Christodoulou GN
    Eur Arch Psychiatry Clin Neurosci; 2006 Sep; 256(6):350-5. PubMed ID: 16900439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of topiramate augmentation in chronic schizophrenia: a placebo-controlled trial.
    Behdani F; Hebrani P; Rezaei Ardani A; Rafee E
    Arch Iran Med; 2011 Jul; 14(4):270-5. PubMed ID: 21726104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study.
    Shiloh R; Zemishlany Z; Aizenberg D; Radwan M; Schwartz B; Dorfman-Etrog P; Modai I; Khaikin M; Weizman A
    Br J Psychiatry; 1997 Dec; 171():569-73. PubMed ID: 9519099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.
    Meltzer HY; Bobo WV; Roy A; Jayathilake K; Chen Y; Ertugrul A; Anil Yağcioğlu AE; Small JG
    J Clin Psychiatry; 2008 Feb; 69(2):274-85. PubMed ID: 18232726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.